Onychomycosis Market Shifts Toward Topical-First Treatment as Global Fungal Nail Infections Rise

The global onychomycosis market is entering a period of sustained expansion as fungal nail infections become increasingly common among aging populations, diabetic patients, and immunocompromised individuals. Rising awareness of nail health, expanding dermatology access, and the emergence of advanced topical antifungal therapies are reshaping treatment preferences across both developed and emerging healthcare markets.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=12023

Quick Market Snapshot

Market Value (2025) USD: 3.96 Billion
Forecast Value (2036): USD 6.7 Billion
CAGR (2026-2036): 4.9%
Leading Infection Type: Distal Subungual Onychomycosis
Leading Distribution Channel: Retail Pharmacies
Fastest Growing Markets: India, China
Key Treatment Trend: Advanced topical antifungals
Key Players: Bausch Health Companies Inc., GSK plc, Abbott, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Cipla, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd.

Rising Disease Burden Expands Treatment Demand

Onychomycosis, a chronic fungal nail infection affecting toenails and fingernails, is becoming more prevalent globally due to aging demographics, diabetes prevalence, poor circulation disorders, and rising lifestyle-related health conditions.

Healthcare providers are also witnessing increased patient presentation rates as awareness improves regarding available treatment options. Historically, many patients delayed treatment because of long therapy durations and concerns around oral antifungal side effects. However, newer topical formulations are changing the treatment landscape by offering safer and more convenient alternatives.

The growing expansion of dermatology clinics and pharmacy-led care channels in emerging economies is further improving diagnosis and treatment accessibility.

Topical Therapies Reshape the Market

One of the most significant shifts within the market is the growing preference for topical-first treatment strategies. Advanced topical antifungal formulations with improved nail penetration technology are gaining traction as they narrow the efficacy gap with oral systemic antifungals.

These products are increasingly preferred for mild-to-moderate infections because they avoid hepatotoxicity concerns and eliminate the need for liver function monitoring commonly associated with oral therapies.

According to industry analysts, the commercial opportunity is rapidly shifting toward prescription and over-the-counter topical products positioned as first-line therapy. Improved patient compliance and lower systemic risk profiles are accelerating this transition.

At the same time, over-the-counter antifungal products are expanding the self-care market, particularly among younger consumers and patients seeking early-stage treatment without specialist consultation.

Distal Subungual Onychomycosis Leads Market Share

Distal Subungual Onychomycosis (DSO) is expected to account for approximately 40% of the infection type segment in 2026, making it the dominant category globally.

Its prevalence is linked to its broad occurrence across primary patient populations and its strong representation in dermatology treatment protocols. Other infection types, including White Superficial and Proximal Subungual Onychomycosis, continue to contribute to market diversification, particularly in specialized clinical cases.

Retail pharmacies are projected to account for nearly 58% of distribution channel demand in 2026, reflecting strong consumer reliance on accessible antifungal products and growing OTC penetration.

Asia-Pacific Emerges as the Fastest-Growing Region

Asia-Pacific is projected to register the strongest growth during the forecast period, led by India and China.

India's onychomycosis market is forecast to expand at a CAGR of 7.1% through 2036, supported by healthcare infrastructure development, rising dermatology awareness, and expanding pharmaceutical access. China follows closely at 6.4% CAGR, driven by broader healthcare coverage and increasing adoption of topical therapies.

North America continues to hold a leading market position due to established healthcare infrastructure, high diagnosis rates, and strong prescription drug penetration. Europe maintains stable growth supported by aging populations and standardized clinical treatment pathways.

Emerging markets across Latin America and the Middle East are also witnessing gradual demand growth as healthcare access improves and pharmacy networks expand.

Competitive Landscape Focuses on Innovation and Distribution

The market remains moderately fragmented, with major pharmaceutical companies competing through broad treatment portfolios, regional distribution capabilities, and formulation innovation.

Leading companies include Bausch Health Companies Inc., GSK plc, Abbott, Pfizer Inc., Bayer AG, and Teva Pharmaceutical Industries Ltd..

Competition is increasingly centered around product efficacy, enhanced nail penetration technology, pricing flexibility, and OTC market expansion. Companies are also strengthening regional partnerships and pharmacy distribution networks to improve market reach.

Future Outlook

The onychomycosis market is expected to evolve steadily as healthcare systems shift toward earlier diagnosis, topical-first management, and consumer-led treatment models. Advanced topical therapies are likely to remain the industry's strongest growth engine, particularly as patients seek safer long-term treatment alternatives with fewer systemic complications.

As awareness increases and dermatology access expands globally, the market is positioned for sustained demand growth across both prescription and self-care treatment segments.

Browse Full Report - https://www.factmr.com/report/onychomycosis-market

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/checkout/12023

To View Related Report:

Dermatophytic Onychomycosis Therapeutic Market https://www.factmr.com/report/dermatophytic-onychomycosis-therapeutic-market

Corneal Topographers Market https://www.factmr.com/report/corneal-topographers-market

Kidney Stone Management Devices Market https://www.factmr.com/report/1827/kidney-stone-management-devices-market

Medical Nonwoven Disposables Market https://www.factmr.com/report/medical-nonwoven-disposables-market

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.